Elevra Lithium Fast-Tracks Expansion Plan, Targeting 315ktpa Production by 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ELV?
Source: Globenewswire
- Optimized Expansion Pathway: Elevra has identified a shorter expansion pathway utilizing new permitting information, aiming to increase spodumene concentrate production to 315ktpa, completing approximately two years ahead of previous plans, significantly enhancing the company's competitive position in the lithium market.
- Phased Investment Strategy: The new strategy staggers capital expenditures, with an initial 15-20% increase in spodumene concentrate production expected to commence in mid-CY27, thereby reducing unit operating costs and enhancing financial flexibility.
- Production Capacity Enhancement: Plans to expand downstream milling, flotation, and filtration capacity to 6,500 tpd are anticipated to commence in early CY28, further lowering unit costs and improving overall production efficiency, thereby strengthening long-term profitability.
- Strong Economic Metrics: Despite adjustments to C1 unit cash costs to $630 per tonne, Elevra's project NPV remains approximately $950 million with an IRR of 26.4%, demonstrating the economic attractiveness and feasibility of the expansion plan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 319.360
Low
332.00
Averages
389.07
High
425.00
Current: 319.360
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Elevance Health Faces Legal Investigation Over Medicare Compliance Issues
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Elevance Health for potential violations of federal securities laws and other unlawful business practices, indicating significant legal risks for the company.
- CMS Sanction Notification: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions, suspending enrollment of Medicare beneficiaries in its Medicare Advantage-Prescription Drug plans, which could adversely affect the company's future customer base and revenue.
- Significant Stock Price Drop: Following the sanction news, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, representing an 8.1% decline, reflecting market concerns over the company's compliance issues.
- Investor Rights Protection: Bragar Eagel & Squire is soliciting Elevance shareholders to discuss their legal rights, encouraging affected investors to reach out to attorneys, suggesting that the ongoing legal challenges may impact shareholder confidence and market performance.
See More
US Navy Seizes Iranian Cargo Ship, Sparking Market Concerns
- Navy Seizure Incident: President Trump announced the U.S. Navy seized an Iranian cargo ship, leading to a cautious market sentiment as investor concerns about Middle Eastern tensions rise, causing oil prices to increase and potentially impacting consumer spending.
- Oil Price Warning: The Energy Secretary warned that gas prices could remain above $3 per gallon until next year, which would negatively affect consumers already feeling the pinch of high costs, further impacting economic recovery.
- Tech and Finance Intersection: Kevin Warsh, Trump's nominee for Federal Reserve Chair, is set for a Senate confirmation hearing, and his close ties to Silicon Valley could change the interaction between tech giants and the Fed, influencing future monetary policy.
- Automotive Dealer Consolidation Trend: Data shows that the top 150 auto dealers in the U.S. increased their market share from 21.2% a decade ago to 27%, reflecting the rise of mega-dealers and the struggles of smaller competitors, potentially leading to significant industry structural changes.
See More
US Navy Seizes Iranian Cargo Ship, Market Sentiment Shifts
- Navy Seizure Incident: President Trump announced that the U.S. Navy seized an Iranian cargo ship in the Gulf of Oman, shifting market sentiment to a defensive stance as investor concerns about Middle Eastern tensions rise, leading to higher oil prices and downward pressure on stock futures.
- Oil Price Warning: Amid fears of escalating tensions in the Middle East, oil prices are rising, with the Energy Secretary warning that gas prices could remain above $3 per gallon until next year, further straining consumers already facing higher costs.
- Tech Ties and Fed: Kevin Warsh, Trump's nominee for the Federal Reserve chair, will face confirmation hearings tomorrow, with his close ties to Silicon Valley raising questions about potential access for tech moguls to the Fed, a point of significant market interest.
- Dealer Consolidation: Data shows that the top 150 car dealerships in the U.S. increased their market share from 21.2% a decade ago to 27%, reflecting a trend of consolidation that benefits larger dealers like Lithia Motors and AutoNation.
See More
ELEVANCE HEALTH: JEFFERIES LOWERS TARGET PRICE FROM $395 TO $391
- Stock Price Adjustment: Jeffries has reduced the target price for Elevance Health from $395 to $391.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Elevance Health's performance.
See More
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Elevance Health Faces Legal Investigation Over Medicare Compliance Issues
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Elevance Health for potential violations of federal securities laws and other unlawful business practices, indicating significant legal risks for the company.
- CMS Sanction Notification: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions, suspending enrollment of Medicare beneficiaries in its Medicare Advantage-Prescription Drug plans, which could adversely affect the company's future customer base and revenue.
- Significant Stock Price Drop: Following the sanction news, Elevance's stock price plummeted from $320.00 on February 27, 2026, to $294.07, representing an 8.1% decline, reflecting market concerns over the company's compliance issues.
- Investor Rights Protection: Bragar Eagel & Squire is soliciting Elevance shareholders to discuss their legal rights, encouraging affected investors to reach out to attorneys, suggesting that the ongoing legal challenges may impact shareholder confidence and market performance.
See More
US Navy Seizes Iranian Cargo Ship, Sparking Market Concerns
- Navy Seizure Incident: President Trump announced the U.S. Navy seized an Iranian cargo ship, leading to a cautious market sentiment as investor concerns about Middle Eastern tensions rise, causing oil prices to increase and potentially impacting consumer spending.
- Oil Price Warning: The Energy Secretary warned that gas prices could remain above $3 per gallon until next year, which would negatively affect consumers already feeling the pinch of high costs, further impacting economic recovery.
- Tech and Finance Intersection: Kevin Warsh, Trump's nominee for Federal Reserve Chair, is set for a Senate confirmation hearing, and his close ties to Silicon Valley could change the interaction between tech giants and the Fed, influencing future monetary policy.
- Automotive Dealer Consolidation Trend: Data shows that the top 150 auto dealers in the U.S. increased their market share from 21.2% a decade ago to 27%, reflecting the rise of mega-dealers and the struggles of smaller competitors, potentially leading to significant industry structural changes.
See More
US Navy Seizes Iranian Cargo Ship, Market Sentiment Shifts
- Navy Seizure Incident: President Trump announced that the U.S. Navy seized an Iranian cargo ship in the Gulf of Oman, shifting market sentiment to a defensive stance as investor concerns about Middle Eastern tensions rise, leading to higher oil prices and downward pressure on stock futures.
- Oil Price Warning: Amid fears of escalating tensions in the Middle East, oil prices are rising, with the Energy Secretary warning that gas prices could remain above $3 per gallon until next year, further straining consumers already facing higher costs.
- Tech Ties and Fed: Kevin Warsh, Trump's nominee for the Federal Reserve chair, will face confirmation hearings tomorrow, with his close ties to Silicon Valley raising questions about potential access for tech moguls to the Fed, a point of significant market interest.
- Dealer Consolidation: Data shows that the top 150 car dealerships in the U.S. increased their market share from 21.2% a decade ago to 27%, reflecting a trend of consolidation that benefits larger dealers like Lithia Motors and AutoNation.
See More
ELEVANCE HEALTH: JEFFERIES LOWERS TARGET PRICE FROM $395 TO $391
- Stock Price Adjustment: Jeffries has reduced the target price for Elevance Health from $395 to $391.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Elevance Health's performance.
See More
